Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000919574-25-004712
Filing Date
2025-08-13
Accepted
2025-08-13 19:29:01
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9919
2 d11955850_ex99-a.htm EX-99 4648
3 d11955850_ex99-b.htm EX-99 806
  Complete submission text file 0000919574-25-004712.txt   17209
Mailing Address 540 MADISON AVENUE 7TH FLOOR NEW YORK NY 10022
Business Address 540 MADISON AVENUE 7TH FLOOR NEW YORK NY 10022 2127025204
SUVRETTA CAPITAL MANAGEMENT, LLC (Filed by) CIK: 0001569064 (see all company filings)

EIN.: 453704500 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269
Business Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269 240-780-6356
ArriVent BioPharma, Inc. (Subject) CIK: 0001868279 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-94331 | Film No.: 251213611
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)